Pancreatic Cancer Vaccine BNT122: Phase 2 Trial Doubles Recurrence-Free Survival
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-06-03 · 8 min read
BioNTech's personalized mRNA vaccine for pancreatic cancer is delivering unprecedented Phase 2 results. Here is what oncologists are watching.
The Hardest Cancer Meets mRNA Tech
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival of just 12%. BNT122 (autogene cevumeran) from BioNTech and Genentech aims to change that.
Phase 1/2 Results
- 50% of vaccine responders recurrence-free at 18 months
- Non-responders: median recurrence at 13 months
- T-cell response durable to 3 years
How It Works
- Surgery removes tumor
- Whost-exome sequencing identifies 20 neoantigens
- mRNA vaccine manufactured in 6 weeks
- 9 priming doses + atezolizumab + chemotherapy + boosters
Phase 3 Status
IMCODE-004 enrolling 260 resected PDAC patients globally, primary endpoint DFS at 36 months. Readout expected late 2027.
This is the most promising pancreatic cancer breakthrough in 30 years.